Iridex Corp. (IRIX) intrinsic value & 10-year financials

Iridex Corp. (IRIX) has a Graham intrinsic value of $11.01 per share. At $0.81 on Oct 17, 2026, the stock trades 93% below that value. Over the last 10 fiscal years revenue grew 2.3% a year to $52.7M, with an average return on invested capital of -103.6%.

Graham intrinsic value
$11.01
Share price (Oct 17, 2026)
$0.81
Price vs Graham value
93% below
Market cap
$13.8M
Revenue (FY2026)
$52.7M
Revenue growth (10-yr CAGR)
2.3%
ROIC (10-yr avg)
-103.6%
Free cash flow (FY2026)
-$2.3M

IRIX 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2026 $52.7M -$4.4M -$0.26 -$2.3M -4.9% -232.4%
FY2024 $48.7M -$8.9M -$0.54 -$7.3M -17.1% -222.6%
FY2023 $51.9M -$9.6M -$0.59 -$6.9M -19.3% -241.7%
FY2022 $57.0M -$7.5M -$0.47 -$9.8M -13.2% -120.1%
FY2021 $36.3M -$6.3M -$0.46 -$3.3M -18.1% -64.6%
FY2019 $43.4M -$8.8M -$0.64 -$8.0M -20.7% -75.7%
FY2018 $42.6M -$12.8M -$1.05 -$10.5M -30.2% -42.6%
FY2017 $41.6M -$12.9M -$1.11 -$4.1M -31.0% -36.6%
FY2016 $46.2M -$11.7M -$1.15 -$1.2M -5.6% -7.0%
FY2015 $42.8M $10.0M $0.97 $3.4M 6.0% 7.7%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

IRIDEX CORP has demonstrated mature, steady growth, with revenue compounding at 2.3% annually over the past decade.

IRIDEX CORP has historically struggled to out-earn its cost of capital, averaging just -34.6% ROIC.

IRIDEX CORP has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, IRIDEX CORP is modeled at 2.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $11.01 per share.

IRIX stock: frequently asked questions

What is the intrinsic value of Iridex Corp. (IRIX) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 2.3% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, IRIX's intrinsic value is about $11.01 per share.

Is IRIX stock undervalued?

At $0.81 (close on Oct 17, 2026), IRIX trades 93% below its Graham value of $11.01. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Iridex Corp. grown?

Revenue went from $42.8M in fiscal 2015 to $52.7M in fiscal 2026, a compound annual growth rate of 2.3%. Net income was -$4.4M in fiscal 2026.

Does Iridex Corp. generate free cash flow?

Iridex Corp. generated -$2.3M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2026. Free cash flow was positive in 1 of the last 10 reported years.

What is IRIX's return on invested capital?

Average ROIC over the last 10 fiscal years was -103.6%, and average return on equity was -54.2%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this IRIX data come from?

From Iridex Corp.'s annual 10-K filings on SEC EDGAR, most recently filed May 19, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar electromedical & electrotherapeutic apparatus stocks